AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...

The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.

AstraZeneca said the “cornerstone” of the commitment would be a new weight management production facility for its oral GLP-1 ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

Shares of AstraZeneca were trading at $72.66 as of July 25. Over the last 52-week period, shares are down 7.46%. Given that these returns are generally negative, long-term shareholders are likely ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer, sending the biotech firm's shares surging more than twofold in premarket ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030.

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...